RxDoctor Payments Data

Bulent Atac, MD

Internal Medicine · Bronx, NYNPI 1942375134

Payments from drug & device makers

$646,621in general payments, 2019–2025

Across 2,081 payments — averaging $310.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$299K
  • Amgen$95K
  • Novo Nordisk$93K
  • Lilly USA, LLC$42K
  • Esperion Therapeutics, Inc.$30K
  • Biohaven Pharmaceuticals, Inc.$22K
  • plus $65K from 52 others

What the payments were for

  • Consulting fees$23,6144%
  • Speaking & faculty fees$511,03679%
  • Travel & lodging$64,81110%
  • Food & beverage$46,6607%
  • Education$4410%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca479$299,432
Amgen(2 entities)210$95,431
Novo Nordisk233$92,628
Lilly USA, LLC143$42,387
Esperion Therapeutics, Inc.81$29,576
Biohaven Pharmaceuticals, Inc.66$22,421
Boehringer Ingelheim92$22,061
Idorsia Pharmaceuticals US Inc41$17,992
Biohaven Pharmaceutical Holding Company Ltd.19$6,183
AbbVie(2 entities)126$5,699
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC95$1,911
Bayer39$1,850
GSK41$895
Amarin Pharma, Inc.56$825
Pfizer41$755
Currax Pharmaceuticals LLC46$579
Astrazeneca UK Limited1$555
Abbott25$519
Kowa Pharmaceuticals America, Inc.35$497
Radius Health, Inc.21$482
Ironwood Pharmaceuticals, Inc17$381
Sanofi-aventis U.S. LLC20$352
Amneal Pharmaceuticals LLC21$302
Novartis14$274
Azurity Pharmaceuticals, Inc.14$260
Astellas Pharma US Inc3$247
Boston Scientific2$242
Johnson & Johnson7$155
Teva Pharmaceuticals USA, Inc.11$148
Xeris Pharmaceuticals, Inc.8$145
Bausch Health US, LLC5$143
Scilex Pharmaceuticals Inc.16$134
Vifor Pharma, Inc.6$112
Exact Sciences4$109
Corcept Therapeutics4$104
Intra-sana Laboratories3$89
Phathom Pharmaceuticals, Inc.4$76
Merck4$74
Mannkind Corporation1$59
Takeda Pharmaceuticals U.S.A., Inc.3$58
Cardiovascular Systems Inc.1$52
Ardelyx, Inc.2$52
Genentech USA, Inc.2$45
Bristol Myers Squibb2$40
Shield Therapeutics Inc2$36
Gilead2$34
Upsher-smith Laboratories LLC1$28
Regeneron Healthcare Solutions, Inc.2$28
IBSA Pharma Inc.1$21
Krystal Biotech Inc1$21
Arbor Pharmaceuticals, Inc.1$20
Circassia Inc.1$19
Dexcom, Inc.1$17
Theracosbio, LLC1$17
Alfasigma USA, Inc.1$14
Philips North America LLC1$14
E.r. Squibb & Sons, L.L.C.1$11
Althera Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646,621 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,717
Medicare patients
87
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide248$400,292
FarxigaDapagliflozin Propanediol136$191,396
RybelsusSemaglutide57$104,619
Xigduo XrDapaglifloz Propaned/Metformin72$100,032
MounjaroTirzepatide67$97,136
VascepaIcosapent Ethyl105$84,542
KerendiaFinerenone56$80,580
Repatha SureclickEvolocumab61$52,449
JardianceEmpagliflozin37$44,433
Bydureon BciseExenatide Microspheres18$36,891
TrulicityDulaglutide20$34,359
NexlizetBempedoic Acid/Ezetimibe30$27,570
DapagliflozinDapagliflozin Propanediol29$26,076
Cinacalcet Hcl11$24,758
ProliaDenosumab14$23,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$92,628$504,911305 claims
AstraZenecaFarxiga$299,432$191,396136 claims
Lilly USA, LLCMounjaro, Trulicity$42,387$131,49587 claims
BayerKerendia$1,850$80,58056 claims
Boehringer IngelheimJardiance$22,061$44,43337 claims
Esperion Therapeutics, Inc.Nexlizet$29,576$27,57030 claims
AmgenProlia$95,431$23,82114 claims
NovartisEntresto$274$19,40413 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$352$16,65113 claims
PfizerEliquis$755$12,95615 claims
GSKTrelegy Ellipta$895$7,27611 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$20$6,87115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →